Quinnipiac university

First Recorded Case of Vibrio vulnificus in Summer 2023 East Coast Outbreak

Amanda McGinn PA-S, Caitlin Reynolds PA-C

Quinnipiac University Graduate Physician Assistant Program, North Haven, CT Lawrence and Memorial Hospital, Department of General Surgery, New London, CT

Introduction

- Vibrio vulnificus (V. vulnificus) is a gram-negative, curved, motile bacterium. 1-3
- V. vulnificus infections are acquired through consumption of raw or undercooked shellfish or contact of an open wound with warm, brackish seawater 1-2
- There are approximately 150 to 200 infections of V. vulnificus yearly in the United States with a mortality rate of 30 to 40%.¹⁻²
- Individuals with any chronic condition are at a significantly higher risk for infection, with the highest risk lying in patients with chronic liver disease at 97% risk of infection with exposure.²
- Patients with primary infection of V. vulnificus typically develop sepsis with rapidly developing ecchymosis and bullae which can progress into necrotizing fasciitis in severe cases.⁴
- Routine blood cultures should be preformed when V. vulnificus is suspected due to the high incidence of sepsis.⁵
- Laboratory results with a concurrent V. vulnificus infection will typically show a marked left shift in white blood cell count, renal injury with a rising serum creatinine, and an elevated creatinine kinase when necrotizing fasciitis is present.⁶
- First line management is antibiotic therapy with aggressive supportive therapy and potential surgical intervention. Patients presenting with hemorrhagic bullae or signs of necrotizing infection should receive prompt surgical debridement.7
- An east coast outbreak began in July 2023 thought to be a result of increased bacterial colonization secondary to extensive heat waves. The first three recorded cases were in Connecticut, two of which resulted in fatalities 1

References

- vibrio vulnificus infections in the United States associated with warming coastal waters. Centers for Disease Control and Prevention. August 31, 2023. Accessed December 3, 2023. https://emergency.cdc.gov/han/2023/han00497.asp#~text=About%20150%E2%80%93200%20V,salt%20water%20and%20fresh%20water
- Shapiro RL, Altekruse S, Hutwagner L, et al. The role of gulf coast oysters harvested in warmer months in vibrio vulnificus infections in the United States 1988-1996 J Infect Dis 1998:178(3):752-759 doi:10.1086/51536
- Hsuch PR, Lin CY, Tang HJ, et al. Vibrio vulnificus in Taiwan. Emerg Infect Dis. 2004;10(8):1363-1368. doi:10.3201/eid1008.040047
- 4. Hlady WG, Klontz KC. The epidemiology of vibrio infections in Florida, 1981-1993. J Infect Dis. 1996; 173(5):1176-1183. doi:10.1093/infdis/173.5.1176
- Li X, Wang C, Guo Z, et al. Enhancing vibrio vulnificus infection diagnosis for negative culture patients with metagenomic next-generation sequencing. Front Cell Infect Microbiol. 2023;13:e1210919. doi:10.3389/fcimb.2023.1210919
- 6. Lerstloompleephunt N, Tantawichien T, Sitprija V. Renal failure in vibrio vulnificus infection. Ren Faul. 2000;22(3):337-343. doi:10.1081/j.di-
- Tsa YH, Hsu RW, Huang KC, Huang TJ Laboratory indicators for early detection and surgical treatment of vibrio necrotizing fascilitis. Clin Orthop Relat Res. 2010;468(8):2230-2237. doi:10.1007/s11999-010-1311-y
- 3. Information for health professionals & laboratorians. Centers for Disease Control and Prevention. August 31, 2023. Accessed December 3, 2023. https://www.cdc.gov/vibrio/healthcare.htm

	Patient's hospital course shown in Figure	
	Detropt's bognital course about in Ligure	
•	Patient S nospital course snown in Figure	

- Seventy-six-year-old Caucasian male
- Past medical history remarkable for atrial fibrillation. Factor V Leiden, and diabetes mellitus.
- Medications: metformin 1000mg PO BID, rivaroxaban 20mg tablet PO daily.
- No known drug allergies.
- · Family history unremarkable.
- Social history remarkable for 5 pack year.

Physical

• ED Visit 2

ED Visit 1

Fig 1. Hospital Course

ED Visit 1.

Discharge Home

Cellulitis of lower leg

Discharged with cefalexin 500

mg capsule PO TID x 7 days

- BP = 138/90 mmHg
- Temp = $98.8^{\circ}F$
- Maroon discoloration of distal left lower leg to ankle
- No calf tenderness

Case Description

History

- Patient visited emergency department (ED) two consecutive days with worsening symptoms.
- ED visit 1 three-day history of left lower leg pain, swelling and redness after walking into a trailer hitch. Reported significant bleeding with swelling and minimal pain day of the accident. Reported nausea and vomiting. Denied calf tenderness or fever
- ED visit 2 returned to emergency department next day. Reported increased swelling with new onset blisters of left lower leg and new onset shortness of breath. Denies fever or chest pain.

2	<u>al</u>			
•	ED Visit 2		D	
	• BP = 142/94 mmHg	•	D	
	• Temp = $101.3 ^{\circ}\text{F}$		th	
	• 2 hemorrhagic bullae on posterior and medial left lower leg as seen in figure 2	•	Fi	
	- 10 1		in	

		U
•	Calf tenderness	present

	ED Visit 2, Admission	Hospital Day 1, Surgery 1	Hospital Day 5, 2
D	Necrotizing soft tissue infection, acute kidney injury, and sepsis	Left lower leg bilateral incision & exploration Subcutaneous tissue edematous and bleeding. Clear serous fluid above fascia with no pus and no necrotic tissue or nuscle.	Pre-operative condition sho Left lower leg fas Left thigh bilateral exploratio Muscle healthy & pink. Co drained No. 1995 or 1995







Diagnostic Results

• ED Visit 1

Labs unremarkable

• ED Visit 2

- X-ray = diffuse left lower extremity edema with no subcutaneous air
- Venous duplex US unable to be completed due to intolerable pain.
- BUN = 51 mg/dL
- Cr = 3.49 mg/dL
- WBC = $18 \times 10^{9}/L$
- Blood cultures positive for Vibrio vulnificus

Surgery 2

• Deep wound cultures positive for *Vibrio* vulnificus

Differential & Final Diagnosis

offerential includes cellulitis, deep vein rombosis, gas gangrene

inal diagnosis - Necrotizing soft tissue infection due to V. vulnificus

, Surgery

own in Figure 3 sciotomy. incision &

lear serous fluid

drained. No pus or necrosis

Hospital Day 12, Discharge

Stable upon discharge to short term rehabilitation facility

Fig 4. Outpatient Follow Up



Patient Management & Follow Up

CDC Guidelines of Antibiotic Therapy for Vibrio vulnificus Wound Infections⁸

- Third generation cephalosporin plus doxycycline is recommended • ex: ceftazidime 1 to 2g IV/IM q8 hrs plus doxycycline 100mg PO/IV BID x 7 to 14 days
- Alternative regimens
 - Third generation cephalosporin plus fluroquinolone
 - Fluroquinolone alone

Antibiotic Therapy

- *Hospital Day 1* patient started on vancomycin 1g in 0.9% NaCl 250mL IVPB, clindamycin 150mg PO q 6hr and piperacillin/tazobactam 3.375g IV q 6hr
- Hospital Day 3 all antibiotics discontinued; patient started on 14-day course of ceftriaxone 1g IV daily, doxycycline 100mg PO BID, and clindamycin 150mg PO q 6hr

Wound Care

- BID dressing changes to all wounds. Wounds packed with gauze soaked in Dankins solution, covered with ABD pads and wrapped with Kerlix.
- *Hospital Day 8* wound VAC placed on thigh wounds

Patient to finish antibiotic course & continue BID dressing changes of left lower leg at short term rehabilitation facility. Patient followed up in office one week after hospital discharge. Lower extremity wounds overall healthy with minimal sloughing as seen in Figure 4. No further need to follow up with surgery service and patient instructed to continue follow up with wound management.

Conclusion

- *V. vulnificus* is a rapidly progressing necrotizing soft tissue infection that requires prompt intervention for successful management.
- Surgical intervention and antibiotic therapy should not be delayed while awaiting culture results and susceptibility testing.
- Individuals with liver disease or immunocompromising conditions are at an increased risk of developing severe V. vulnificus infection, and therefore should avoid open wound exposure to seawater or eating undercooked seafood.
- Although V. vulnificus infections are rare, providers must remain knowledgeable in its presentation and should always be considered when evaluating aquatic related sepsis or necrotizing infections.